SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-008051
Filing Date
2024-02-14
Accepted
2024-02-14 17:16:03
Documents
16
Period of Report
2024-02-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20021723_8k.htm   iXBRL 8-K 44148
2 EXHIBIT 99.1 ef20021723_ex99-1.htm EX-99.1 806229
6 image00001.jpg GRAPHIC 1400
  Complete submission text file 0001140361-24-008051.txt   1043615

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20240208.xsd EX-101.SCH 3908
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20240208_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20240208_pre.xml EX-101.PRE 16073
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20021723_8k_htm.xml XML 4040
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 24640564
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)